Background
Overarching goals of the TANGO study
Specific goals of the TANGO study
Methods/Design
Phase 1 – Data registry
Inclusion and exclusion criteria
IgA nephropathy Membranous glomerulonephritis Focal and segmental glomerulosclerosis Atypical hemolytic uremic syndrome Membranoproliferative glomerulonephritis old classification type I-III Complement- or IgG-positive membranoproliferative glomerulonephritis Dense-deposit disease C3 glomerulonephritis |
Inclusion criteria | Exclusion criteria |
---|---|
1. ≥18 years-old 2. Biopsy proven GD as underlying cause of end-stage kidney disease (listed in Table 2) 3. Recipient of a kidney transplant after 2005, currently functioning or not 4. With/without recurrence of GD | 1. Patients without diagnostic native kidney biopsy 2. Patients with a secondary cause of GD 3. Unable to provide written consenta |
Variables and follow-up
Variables | |
---|---|
Patient demographics | Subject ID, year of birth, gender, race, height, weight |
Kidney history | Cause of kidney disease, dialysis duration, residual urine output, nephrotic proteinuria pre-transplant, native kidney nephrectomy, family history of glomerulonephritis |
Other past medical history | Hypertension, diabetes mellitus, coronary artery disease, hepatitis, cancer, autoimmune disease, others |
Recipient-Donor Transplant details | Date of transplant, preemptive transplant, prior transplant, donor’s characteristics, cold ischemia time, recipient’s panel reactive antibody, HLA mismatch, donor specific antibody prior transplant, crossmatch, delayed graft function, EBV serology, CMV serology, induction and maintenance immunosuppression drugs |
Post-transplant visits (yearly) | Medications, Physical examination, relevant laboratory test post-transplant (including blood and urine), rejection episodes and treatment received, donor specific antibodies development, infections (virus), cancer, other complications, recurrent glomerular disease and treatment |
Patient outcome | Graft failure and cause, patient death and cause |
Database
Data analysis, expected sample size and statistical approach
Disease | Estimated sample size |
---|---|
IgA-nephropathy | 227 |
Membranous nephropathy | 260 |
Focal segmental glomerulosclerosis | 260 |
Membranoproliferative glomerulonephritis | 270 |
Atypical hemolytic uremic syndrome | 270 |
Total | 1287 |